Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260149 | 0.86 | MAPK14 (0.69) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL5258301 | 0.86 | MAPK14 (0.66) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL14411717 | 0.82 | MAPK14 (0.65) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL14521854 | 0.81 | MAPK14 (0.67) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL14521895 | 0.80 | MAPK14 (0.70) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL14521804 | 0.79 | MAPK14 (0.72) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL14411554 | 0.79 | MAPK14 (0.65) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL14411792 | 0.78 | MAPK14 (0.70) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL6331135 | 0.78 | MAPK14 (0.63) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL14411238 | 0.78 | MAPK14 (0.51) | MAPK14MAPK11MAPK13MAPK12KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153959-B2 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-7071198-B1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-6979686-B1 | Substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION (US) | 2005-12-27 | — | — | US | disclosed |
| US-6617324-B1 | Phenyl, cyclohexyl and pyridinyl or pyrimidinyl-substituted | G. D. SEARLE & COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6525059-B1 | Mitogen-activated protein kinases (MAP); | G. D. SEARLE & COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6514977-B1 | For treating p38 kinase mediated disorders | G.D. SEARLE & COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-6423713-B1 | Substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & COMPANY | 2002-07-23 | — | — | US | disclosed |